Dear CoreWeave Stock Fans, Mark Your Calendars for August 14
The artificial intelligence (AI) infrastructure firm is in focus today because its lockup period during which insiders are prohibited from selling shares after the initial public offering (IPO) also ends on Thursday, Aug. 14.
More News from Barchart
'It Will Be the Biggest Product Ever': Elon Musk Says Tesla's Optimus Robots Will Be Bigger Than Even Robotaxi
Dear Archer Aviation Stock Fans, Mark Your Calendars for August 11
This Hidden-Gem AI Stock Has a Major Catalyst Coming on August 11
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
CoreWeave stock has been a lucrative investment in 2025. The company priced its IPO at $40 only but is going for $139 at the time of writing, indicating some 250% return in less than five months.
Why Did JPM Issue a Constructive Note on CoreWeave Stock
Murphy maintained his 'Overweight' rating on CRWV this morning, citing the nearly $12 billion AI data center deal it announced with OpenAI in early March.
'Our sense is that CoreWeave Inc's opportunities are going to get bigger and lumpier, likely to the investors' surprise,' he told clients in a research note on Monday.
JPM issued a constructive note in favor of CRWV shares today also because it sees the company's long-term AI ramp as 'clear' and 'intact,' and sees 'continued momentum in its business pipeline' in the second half of 2025.
Why CRWV Shares Remain a Risky Investment at Current Levels
Investors should note that CoreWeave shares are currently going for a price-sales (P/S) ratio of more than 22x.
While significantly lower compared to Nvidia (NVDA), that multiple still looks overly stretched given the AI infrastructure company is yet to turn a profit. Consensus is for it to lose $0.49 on a per-share basis in its Q2.
Plus, insiders and early investors may sell CRWV en masse as the lockup period expires later this week, especially since the AI stock has experienced nothing short of a cosmic run in recent months.
This profit-taking could trigger a sharp pullback in CRWV stock over the next few weeks.
How Wall Street Recommends Playing CoreWeave
Note that other Wall Street firms recommend caution in playing CoreWeave stock at current levels.
According to the Barchart, the consensus rating on CRWV shares currently sits at 'Hold' only with the mean target of about $96 indicating potential downside of more than 30% from here.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Martinrea International Inc (MRETF) Q2 2025 Earnings Call Highlights: Strong Financial ...
Adjusted Operating Income: $86.1 million, up from $81.6 million in Q2 of last year. Adjusted Operating Income Margin: 6.8%, up 50 basis points year over year. Free Cash Flow (before IFRS 16 lease payments): $72 million, up from $51.7 million in Q2 of last year. Free Cash Flow (including IFRS 16 lease payments): $57.9 million. Adjusted Net Earnings Per Share: $0.66, up from $0.58 in Q2 of 2024. Net Debt: Decreased by approximately $73 million to $792 million. Net Debt to Adjusted EBITDA Ratio: 1.5x, down from 1.64x in Q1. 2025 Outlook: Total sales of $4.8 billion to $5.1 billion, adjusted operating income margin of 5.3% to 5.8%, and free cash flow of $125 million to $175 million. New Business Awards: $40 million in annualized sales, with $18 million from Stellantis and $22 million from Volkswagen and Volvo trucks. Warning! GuruFocus has detected 3 Warning Signs with MRETF. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Martinrea International Inc (MRETF) reported a strong second quarter with stable production levels, good profits, operating margin, and free cash flow. The company achieved notable margin improvements compared to the first quarter, driven by operational enhancements and negotiated commercial recoveries. Martinrea's machine learning initiatives, including adaptive welding software and AI vision systems, have resulted in significant cost savings and efficiency improvements. The company has been awarded new business worth $40 million in annualized sales, indicating a healthy pipeline and growth potential. Martinrea is on track to meet its 2025 outlook, with strong free cash flow generation and a solid balance sheet, maintaining a net debt to adjusted EBITDA ratio of 1.5x. Negative Points The company faces some tariff exposure, particularly from Tier 2 suppliers and parts affected by steel and aluminum tariffs, although it is considered manageable. Production sales are expected to be lower in the second half of the year due to typical seasonal patterns, which may impact margins. There are uncertainties regarding the impact of tariffs and the strength of the US economy in the second half of the year. Commercial recoveries in Europe have been limited, and the timing of these negotiations is somewhat out of the company's control. The company is maintaining a minimal footprint in the Rest of the World segment, which can result in profit swings due to changes in volumes and commercial settlements. Q & A Highlights Q: Can you provide additional commentary on the back-half margin guide, considering the strong margins despite lower sales in North America? A: Peter Cirulis, CFO: The second half will be impacted by seasonal adjustments, with production levels expected to be lower. There were some one-time favorable effects in Q2 that won't repeat in the second half, including contractual price reductions with certain customers. However, we expect a strong performance in the third quarter, with some opacity in the fourth. Q: Are there specific facilities in North America driving productivity and efficiency improvements? A: Pat D'Eramo, CEO: We don't focus on specific facilities, but our lean manufacturing journey is showing results across the board. Some plants are particularly advanced, and our machine learning initiatives are contributing to improvements. Overall, our operations are performing well globally. Q: Will there be any commercial recoveries in Europe in the second half of the year? A: Peter Cirulis, CFO: Commercial recoveries are somewhat unpredictable in terms of timing, but we expect some issues to be resolved in the second half. Over time, we anticipate fewer recoveries as the industry normalizes. Q: How do you view the impact of tariffs on your North American operations, given the strong margins? A: Peter Cirulis, CFO: There was a tariff headwind in Q2, but it was manageable. We expect to recover a large extent of this impact by year-end. The strong margins are also supported by our operational improvements and commercial activities. Q: With discussions on production reshoring, what are the implications for your facilities in Canada and Mexico? A: Pat D'Eramo, CEO: It depends on the source of the work. If it's new work from Asian or European OEMs, we will place it where it makes logistical sense. For work moving within North America, our existing footprint is well-positioned to handle it. This could create opportunities for our Canadian facilities. Q: What is your outlook on CapEx, given the recent trends? A: Peter Cirulis, CFO: We are comfortable with a $300 million CapEx target, but it could vary depending on the cadence of our launches and program extensions. We aim to align CapEx with depreciation. Q: How do you view the valuation of Martinrea compared to US peers, and would you consider re-domiciling to the US? A: Robert Wildeboer, Executive Chairman: We acknowledge the valuation discount and have bought back shares. Re-domiciling has tax implications, but we are aware of the value and will consider different strategies. We believe our shares are undervalued, which is why we've been buying them back. Q: What are your thoughts on the investment in NanoXplore and the potential of graphene? A: Robert Wildeboer, Executive Chairman: We believe graphene has a promising future and have used it in leading-edge products. While we don't use a large quantity, it contributes to our profitability. We are optimistic about its potential applications and the recognition of its value. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 minutes ago
- Yahoo
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...
Research and Development Expenses: $2.1 million for Q2 2025, compared to $15.1 million for Q2 2024. General and Administrative Expenses: $8.6 million for Q2 2025, compared to $7.3 million for Q2 2024. Net Loss: $26.9 million or $0.9 per share for Q2 2025, compared to $20.9 million or $0.9 per share for Q2 2024. Cash and Cash Equivalents: $312.8 million as of June 30, 2025. Follow-on Financing Proceeds: $230 million from May 2025, including full exercise of underwriters' option. Refinanced Loan: New debt facility of $50 million upfront with Trinity Capital, deferring principal payments by over 2.5 years. Warning! GuruFocus has detected 4 Warning Signs with TSHA. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Taysha Gene Therapies Inc (NASDAQ:TSHA) has obtained alignment with the FDA and Health Canada to proceed with initiating their REVEAL pivotal trial for TSHA-102, indicating strong regulatory progress. The company reported positive clinical data supporting the therapeutic potential of TSHA-102, with all 10 patients in Part A of the REVEAL trials gaining or regaining developmental milestones. TSHA-102 is designed to target the genetic root cause of Rett syndrome, leveraging a clinically proven AAV9 vector and a minimally invasive lumbar intrathecal injection method. The company completed a public follow-on offering, resulting in total gross proceeds of $230 million, extending their cash runway into 2028. Taysha Gene Therapies Inc (NASDAQ:TSHA) has a defined path to registration for TSHA-102, with a pivotal trial underway and a strengthened balance sheet. Negative Points The company reported a net loss of $26.9 million for the three months ended June 30, 2025, compared to a net loss of $20.9 million for the same period in 2024. General and administrative expenses increased to $8.6 million for the three months ended June 30, 2025, primarily due to higher legal and professional fees. There are no currently approved therapies that treat the underlying genetic root cause of Rett syndrome, highlighting the urgency and challenge of developing effective treatments. The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements, as noted in their SEC filings. The pivotal trial design relies on a novel regulatory pathway, which may present challenges in terms of regulatory approval and market acceptance. Q & A Highlights Q: Given there was a 100% response rate for the pivotal trial primary endpoint in Part A of the study, is this the bar for Part B in your view? A: Sean Nolan, CEO: The results from Part A are compelling, but maintaining a 100% response rate is challenging. The statistical plan for Part B uses a null hypothesis of 6.7%, meaning only 1 out of 15 patients might spontaneously gain or regain a milestone. The statistical bar is relatively low, around 33%, and the numbers from Part A are significantly above this threshold. Q: Are there certain time points where all milestones are occurring, or are additional ones seen over time? Have the benefits of the gene therapy plateaued? A: Elsa Rosignol, Director of Integrated Rett Syndrome Clinic: We see increasing improvements over time, not just at one visit. Gains occur at most follow-up visits, and some critical gains in daily functioning are not captured in the developmental milestone assessment but are still significant improvements. Q: How does your gene therapy differentiate from competitors, particularly regarding study design and primary endpoints? A: Sean Nolan, CEO: Our approach is unique, focusing on clinically meaningful and objective gains in activities of daily living. We've worked with regulators to establish a new paradigm in assessing clinical efficacy through milestone gains. This approach is supported by KOLs, advocacy groups, and regulators, emphasizing the therapy's impact on quality of life. Q: Would you expect any pushback on using your interim readout to support BLA filing, given your competitor's feedback on a 6-month endpoint? A: Sean Nolan, CEO: Our interim analysis approach is data-driven, based on robust support from Part A data. We've discussed this with the FDA, focusing on further refinements of the analysis rather than overturning key trial design elements. We feel confident about our position. Q: Can you characterize any changes from Part A CMC material batch to Part B, specifically regarding full to empty capsid ratio? How many patients can you supply with commercial-scale material? A: Sean Nolan, CEO: We've aligned with the FDA that Part A and pivotal material are analytically comparable. We've made the product for the pivotal trial with the commercial process at scale. Our cash runway into 2028 allows us to build commercial inventory as needed, ensuring we're well-positioned on the CMC side. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Luminar Technologies Inc (LAZR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...
Revenue: $15.6 million for Q2, down 17% sequentially and 5% year over year. Gross Loss: $12.4 million on a GAAP basis and $10.8 million on a non-GAAP basis for Q2. Operating Expenses: $27 million on a GAAP basis and $47 million on a non-GAAP basis for Q2. Cash and Marketable Securities: $108 million at the end of Q2. Free Cash Flow: Approximately $53 million for Q2. 2025 Revenue Guidance: Lowered to $67 million to $74 million. Sensor Shipments: Expected to be in the range of 20,000 to 23,000 units for 2025, down from previous guidance of 30,000 to 33,000 units. Cost Savings: Expected reduction in operating expenses by $23 million in gross rate annual savings by 2026. Convertible Notes: Reduced face value by approximately $440 million since August of last year. Q3 Revenue Guidance: Expected to be in the range of $17 million to $19 million. Warning! GuruFocus has detected 8 Warning Signs with LAZR. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Luminar Technologies Inc (NASDAQ:LAZR) achieved a major technical milestone by demonstrating the ability to detect objects as small as 8 centimeters at distances over 175 meters, which is considered an industry best. The company is focusing on commercial markets such as trucking, security, and defense, where autonomy and physical space analytics are advancing quickly, providing near-term revenue opportunities. Luminar Technologies Inc (NASDAQ:LAZR) is restructuring its supply chain by transitioning production to Thailand, which is expected to improve unit economics and streamline operations. The company has made significant progress in strengthening its balance sheet by reducing the face value of its 2026 convertible notes by approximately $440 million since August of the previous year. Luminar Technologies Inc (NASDAQ:LAZR) is exiting noncore initiatives, which is expected to reduce operating expenses by nearly $23 million in gross rate annual savings by 2026. Negative Points The widespread adoption of Level 3 and higher autonomy in the automotive market is progressing more slowly than expected, impacting long-term revenue projections. Luminar Technologies Inc (NASDAQ:LAZR) has lowered its 2025 revenue guidance due to a reduction in production volume estimates, particularly for the EX90 program, and the strategic decision to exit noncore areas of the business. The company reported a gross loss of $12.4 million on a GAAP basis for the quarter, which was below guidance due to a $3 million noncash warranty adjustment. There is a sequential decline in revenue, primarily driven by lower-than-expected NRE revenue and a reduction in sensor shipments. The transition of production to Thailand and the winding down of noncore business areas may lead to short-term operational disruptions and revenue impacts. Q & A Highlights Q: Can you help us size the opportunities from adjacent markets and update on potential customer engagements? A: The commercial markets are very large, but specific sizes are not provided today. We expect to leverage the Halo platform in both commercial and automotive markets. Paul Ricci, CEO Q: The shipment of series production sensors was at unfavorable economics. Can you elaborate on that? A: Due to lower-than-expected volume in the EX90 program, we are selling sensors at prices lower than production costs. We are transitioning production to Thailand to improve economics. Thomas Fennimore, CFO Q: When do you expect to realize revenue from commercial markets at a material level? A: We are realizing revenues today and expect to grow them over 2026. It's already a material part of our revenues this year. Paul Ricci, CEO Q: What positions Luminar to succeed in smart applications or infrastructure markets? A: We have existing revenues and technological advantages, offering LiDAR capabilities at lower price points. The market is large and growing rapidly. Paul Ricci, CEO Q: Could you provide an update on the partnership with Mercedes Benz? A: We have a development agreement with Mercedes and are working towards converting it into a production agreement based on milestone achievements. Paul Ricci, CEO Q: How do you see the automotive market evolving, particularly with OEMs and technology partners? A: Most automotive manufacturers are committed to autonomous technology, sourcing LiDAR hardware and software from us. The boundary between what they do and what we do will evolve over time. Paul Ricci, CEO Q: Could you help unpack the downside revision to the full-year revenue guidance? A: About two-thirds of the $15 million delta is due to lower sensor shipments, and the other third is related to the cancellation of the data contract. Thomas Fennimore, CFO Q: What are you hearing from Volvo regarding the EX90 and their future plans? A: Volvo has been an excellent partner and an early leader in LiDAR deployment. We continue to work with them on deployment and production agreements for the next-generation Halo architecture. Paul Ricci, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
